# A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)

> **NCT03485365** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 97 (actual)

## Conditions studied

- Pain, Inflammatory

## Interventions

- **DRUG:** GSK3858279 IV
- **DRUG:** GSK3858279 SC
- **DRUG:** Placebo matching to GSK3858279 (SC or IV)
- **DRUG:** Placebo matching to GSK3858279 (SC)

## Key facts

- **NCT ID:** NCT03485365
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-17
- **Primary completion:** 2022-09-12
- **Final completion:** 2022-09-12
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03485365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03485365, "A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03485365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*